Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care–associated infections in US hospitals. N Engl J Med. 2018;379(18):1732–44.
Google Scholar
Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) – a systematic review of the epidemiology of primary and recurrent CDI. BMC infectious diseases. 2021;21(1):456 PubMed PMID: 34016040. Pubmed Central PMCID: PMC8135979. Epub 2021/05/22. eng.
Google Scholar
Borren NZ, Ghadermarzi S, Hutfless S, Ananthakrishnan AN. The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PloS one. 2017;12(5):e0176797.
Google Scholar
Ghia CJ, Waghela S, Rambhad GS. Systematic Literature Review on Burden of Clostridioides difficile Infection in India. Clinical pathology (Thousand Oaks, Ventura County, Calif). 2021;14:2632010×211013816 PubMed PMID: 34104883. Pubmed Central PMCID: PMC8170333. Epub 2021/06/10. eng.
Google Scholar
Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407. Epub 2019/01/04. eng.
Boven A, Vlieghe E, Engstrand L, Andersson FL, Callens S, Simin J, Brusselaers N. Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study. Clin Microbiol Infect. 2023:S1198-743X(23):00315–4. Epub ahead of print.
Yu H, Flaster N, Casanello AL, Curcio D. Assessing risk factors, mortality, and healthcare utilization associated with Clostridioides difficile infection in four Latin American countries. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2021;25(1):101040.
Google Scholar
Malone DC, Armstrong EP, Gratie D, Pham SV, Amin A. A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections. Antimicrobial stewardship & healthcare epidemiology : ASHE. 2023;3(1):e17.
Google Scholar
Reveles KR, Yang M, Garcia-Horton V, Edwards ML, Guo A, Lodise T, et al. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis. Advances in therapy. 2023;40(7):3104–34 PubMed PMID: 37210680. Pubmed Central PMCID: PMC10272265. Epub 2023/05/21. eng.
Google Scholar
Wingen-Heimann SM, Davies K, Viprey VF, Davis G, Wilcox MH, Vehreschild M, et al. Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023;29(5):651.e1-e8 PubMed PMID: 36586512. Epub 2023/01/01. eng.
Google Scholar
Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC infectious diseases. 2016;16(1):447 PubMed PMID: 27562241. Pubmed Central PMCID: PMC5000548. Epub 2016/08/27. eng.
Google Scholar
Nanwa N, Sander B, Krahn M, Daneman N, Lu H, Austin PC, et al. A population-based matched cohort study examining the mortality and costs of patients with community-onset Clostridium difficile infection identified using emergency department visits and hospital admissions. PloS one. 2017;12(3):e0172410. PubMed PMID: 28257438. Pubmed Central PMCID: PMC5336215. Epub 2017/03/04. eng.
Google Scholar
Shorr AF, Zilberberg MD, Wang L, Baser O, Yu H. Mortality and Costs in Clostridium difficile Infection Among the Elderly in the United States. Infect Control Hosp Epidemiol. 2016;37(11):1331–6 PubMed PMID: 27572289. Epub 2016/10/22. eng.
Google Scholar
Braae UC, Møller FT, Ibsen R, Ethelberg S, Kjellberg J, Mølbak K. The Economic Burden of Clostridioides difficile in Denmark: A Retrospective Cohort Study. Frontiers in public health. 2020;8:562957. PubMed PMID: 33324595. Pubmed Central PMCID: PMC7725905. Epub 2020/12/17. eng.
Google Scholar
Son KJ, Kim YA, Park YS. Economic burden attributable to Clostridioides difficile infections in South Korea: a nationwide propensity score-matched study. The Journal of hospital infection. 2022;120:1–8 PubMed PMID: 34774670. Epub 2021/11/15. eng.
Google Scholar
Kuntz JL, Baker JM, Kipnis P, Li SX, Liu V, Xie Y, et al. Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study. Infect Control Hosp Epidemiol. 2017;38(1):45–52 PubMed PMID: 27760583. Pubmed Central PMCID: PMC5532139. Epub 2016/10/21. eng.
Google Scholar
Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care-associated infections: mind your p’s and q’s. Clin Infect Dis. 2010;50(7):1017–21.
Google Scholar
Sahrmann JM, Olsen MA, Stwalley D, Yu H, Dubberke ER. Costs Attributable to Clostridioides difficile Infection Based on the Setting of Onset. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023;76(5):809–15 PubMed PMID: 36285546. Pubmed Central PMCID: PMC10226732. Epub 2022/10/27. eng.
Google Scholar
Sahrmann JM, Olsen MA, Keller MR, Yu H, Dubberke ER. Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults. Open forum infectious diseases. 2023;10(7):ofad343 PubMed PMID: 37496610. Pubmed Central PMCID: PMC10368308. Epub 2023/07/27. eng.
Google Scholar
Durovic A, Widmer AF, Frei R, Tschudin-Sutter S. Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations. Infect Control Hosp Epidemiol. 2017;38(8):891–6 PubMed PMID: 28592348. Epub 2017/06/09.
Google Scholar
Moreels N, Boven A, Gressani O, Andersson FL, Vlieghe E, Callens S, et al. The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence. The Journal of antimicrobial chemotherapy. 2024;79(3):608–16 PubMed PMID: 38267263. Pubmed Central PMCID: PMC10904719. Epub 2024/01/25.
Google Scholar
Mpakaniye P, Boven A, Callens S, Engstrand L, Vlieghe E, Brusselaers N. Clostridioides difficile recurrence in individuals with and without cancer: a Swedish population-based cohort study. Infection. 2024;52(2):649–60 PubMed PMID: 38407777. Pubmed Central PMCID: PMC10954957. Epub 2024/02/26.
Google Scholar
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and drug safety. 2007;16(7):726–35 PubMed PMID: 16897791. Epub 2006/08/10. eng.
Google Scholar
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. European journal of epidemiology. 2009;24(11):659–67 PubMed PMID: 19504049. Pubmed Central PMCID: PMC2773709.
Google Scholar
Brusselaers N, Lagergren J. The Charlson Comorbidity Index in Registry-based Research. Methods Inf Med. 2017;56(5):401–6 PubMed PMID: 29582935.
Google Scholar
Nelson WW, Scott TA, Boules M, Teigland C, Parente A, Unni S, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. 2021;27(7):828–38 PubMed PMID: 33703939.
Google Scholar
Nordling S, Anttila VJ, Noren T, Cockburn E. The Burden of Clostridium Difficile (CDI) Infection in Hospitals, in Denmark, Finland, Norway And Sweden. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014;17(7):A670 PubMed PMID: 27202459. Epub 2014/11/01. eng.
Google Scholar
van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls C, Dekkers OM, Kuijper EJ, Keller JJ, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022;28(3):321–31 PubMed PMID: 34655745. Epub 2021/10/17. eng.
Google Scholar
Singh H, Nugent Z, Walkty A, Yu BN, Lix LM, Targownik LE, et al. Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study. PloS one. 2019;14(11):e0224609. Epub 2019/11/09. eng.
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450 PubMed PMID: 21658213. Pubmed Central PMCID: 3142234. Epub 2011/06/11. eng.
Google Scholar
Forsberg L RH, Jacobsson A, Nyqvist K, Heurgren M. Kvalitet och innehåll i patientregistret. Utskrivningar från slutenvården 1964–2007 och besök i specialiserad öppenvård (exklusive primärvårdsbesök) 1997–2007. Stockholm: Socialstyrelsen; 2008. Accessed 02 May 2024.
Rizzardi K, Noren T, Aspevall O, Makitalo B, Toepfer M, Johansson A, et al. National Surveillance for Clostridioides difficile Infection, Sweden, 2009–2016. Emerging infectious diseases. 2018;24(9):1617–25 PubMed PMID: 30124193. Pubmed Central PMCID: PMC6106436. Epub 2018/08/21.
Google Scholar
Marra AR, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang HY, et al. Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(1):e1917597. PubMed PMID: 31913488. Pubmed Central PMCID: PMC6991241. Epub 2020/01/09.
Google Scholar
Socialstyrelsen. The Swedish Prescribed Drug Register 2020 [updated 21–8–202130–9–2021]. Available from: https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-swedish-prescribed-drug-register/.
Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. 2018;8(7): e021869.
Google Scholar
Socialstyrelsen;. The Causes of Death Register 2018 [updated 2019–05–29]. Available from: https://www.socialstyrelsen.se/statistik-och-data/register/dodsorsaksregistret/bortfall-och-kvalitet/.
Cançado GGL, Abreu ES, Nardelli MJ, Serwa P, Brachmann M. A cost of illness comparison for toxigenic Clostridioides difficile diagnosis algorithms in developing countries. Anaerobe. 2021;70:102390. PubMed PMID: 34058377. Epub 2021/06/01. eng.
Google Scholar
Yu H, Alfred T, Nguyen JL, Zhou J, Olsen MA. Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023;76(3):e1476–83 PubMed PMID: 35686435. Pubmed Central PMCID: PMC9907506. Epub 2022/06/11. eng.
Google Scholar
Wilcox MH, Ahir H, Coia JE, Dodgson A, Hopkins S, Llewelyn MJ, et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. The Journal of antimicrobial chemotherapy. 2017;72(9):2647–56 PubMed PMID: 28633368. Epub 2017/06/22. eng.
Google Scholar
Paschos P, Ioakim K, Malandris K, Koukoufiki A, Nayfeh T, Akriviadis E, et al. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Anaerobe. 2021;71:102441. PubMed PMID: 34454094. Epub 2021/08/29. eng.
Google Scholar
Richardson M, Erman A, Daneman N, Miller FA, Sander B. Defining the decision problem: a scoping review of economic evaluations for Clostridioides difficile interventions. The Journal of hospital infection. 2022;121:22–31 PubMed PMID: 34813872. Epub 2021/11/24. eng.
Google Scholar
Gupta A, Ananthakrishnan AN. Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therap Adv Gastroenterol. 2021;14:17562848211018654 PubMed PMID: 34104214. Pubmed Central PMCID: PMC8170348. Epub 2021/06/10. eng.
Google Scholar
Swart N, Sinha AM, Bentley A, Smethurst H, Spencer G, Ceder S, et al. A cost-utility analysis of two Clostridioides difficile infection guideline treatment pathways. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023;29(10):1291–7 PubMed PMID: 37356620. Epub 2023/06/26. eng.
Google Scholar
link